Patents by Inventor Gary S. Jacob

Gary S. Jacob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination drug therapy for glycolipid storage diseases
    Publication number: 20020127213
    Abstract: A novel combination drug therapy is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of both a N-alkyl derivative of deoxynojirimycin (DNJ) and a glucocerebrosidase enzyme to alleviate or inhibit the glycolipid storage disease. The alkyl group has from about two to about 20 carbon atoms and preferably is butyl, nonyl or decyl.
    Type: Application
    Filed: January 22, 2002
    Publication date: September 12, 2002
    Inventors: Gary S. Jacob, Raymond A. Dwek
  • Combination drug therapy for glycolipid storage diseases
    Publication number: 20010044453
    Abstract: A novel combination drug therapy is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of both a N-alkyl derivative of deoxynojirimycin (DNJ) and a glucocerebrosidase enzyme to alleviate or inhibit the glycolipid storage disease. The alkyl group has from about two to about 20 carbon atoms and preferably is butyl, nonyl or decyl.
    Type: Application
    Filed: May 17, 2001
    Publication date: November 22, 2001
    Inventors: Gary S. Jacob, Raymond A. Dwek
  • Use of alkylated iminosugars to treat multidrug resistance
    Patent number: 6225325
    Abstract: Methods and compositions for preventing, reducing, or reversing multidrug resistance (MDR) during cancer chemotherapy in patients undergoing treatment with therapeutically effective amounts of chemotherapeutic agents are provided. The methods comprise administering an anti-MDR effective amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol iminosugar to a patient.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: May 1, 2001
    Assignee: G.D. Searle & Company
    Inventor: Gary S. Jacob
  • Compound, N-butyl-deoxynojirimycin-6-phosphate
    Patent number: 5103008
    Abstract: A method is provided for converting therapeutic glycosidase inhibitors to novel prodrugs by phosphorylation of a free hydroxyl group on the molecule to substantially reduce the glycosidase inhibitory activity without thereby substantially reducing the therapeutic activity.
    Type: Grant
    Filed: April 12, 1991
    Date of Patent: April 7, 1992
    Assignee: Monsanto Company
    Inventors: Peter R. Scudder, Raymond A. Dwek, Thomas W. Rademacher, Gary S. Jacob
  • Phosphorylated glycosidase inhibitor prodrugs
    Patent number: 5043273
    Abstract: A method is provided for converting therapeutic glycosidase inhibitors to novel prodrugs by phosphorylation of a free hydroxyl group on the molecule to substantially reduce the glycosidase inhibitory activity without thereby substantially reducing the therapeutic activity.
    Type: Grant
    Filed: August 17, 1989
    Date of Patent: August 27, 1991
    Assignee: Monsanto Company
    Inventors: Peter R. Scudder, Raymond A. Dwek, Thomas W. Rademacher, Gary S. Jacob
  • Method of treating herpesviruses
    Patent number: 4957926
    Abstract: A method is disclosed for the treatment of herpesvirus infections comprising treating the infected host with an effective amount of an N-alkyl derivative of deoxynojirimycin in which the alkyl group contains from one to about six carbon atoms, and preferably is butyl.
    Type: Grant
    Filed: December 22, 1988
    Date of Patent: September 18, 1990
    Assignee: Monsanto Company
    Inventors: Gary S. Jacob, A. Stanley Tyms, Thomas W. Rademacher, Raymond A. Dwek